secwatch.observer — SEC 8-K summary
======================================

Issuer:     Design Therapeutics, Inc. (DSGN)
CIK:        0001807120
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021862
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Design Therapeutics reports Q3 net loss $17.7M; cash $344.2M; DT-216 Phase 1 SAD data in Dec 2022
--------------------------------------------------------------------------------

- Net loss of $17.7M for Q3 2022; R&D expenses $14.3M, G&A expenses $4.9M.
- Cash, equivalents and securities of $344.2M as of Sept 30, 2022, supporting multi-year runway.
- Initial data from DT-216 single-ascending dose Phase 1 for Friedreich Ataxia expected Dec 2022.
- Multiple-ascending dose Phase 1 dosing initiated; completion anticipated mid-2023.
- DM1 GeneTAC program preclinical; clinical development expected to begin in 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1807120/000095017022021862/0000950170-22-021862-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1807120/000095017022021862/dsgn-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021862

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer